RxDoctor Payments Data

Neil Shachter, MD

Cardiovascular Disease · Delray Beach, FLNPI 1942336516

Payments from drug & device makers

$7,293in general payments, 2019–2025

Across 16 payments — averaging $455.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$7K
  • Sanofi-aventis U.S. LLC$100
  • Vifor Pharma, Inc.$80
  • E.r. Squibb & Sons, L.L.C.$40
  • Amgen$23
  • Pfizer$18
  • plus $16 from 1 others

What the payments were for

  • Speaking & faculty fees$6,90095%
  • Travel & lodging$981%
  • Food & beverage$2143%
  • Education$801%

General payments by program year

19
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,293 in reported general payments places this provider in the 65th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$44,288
Medicare patients
516
Services billed
1,174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban89$102,084
FarxigaDapagliflozin Propanediol77$86,017
EntrestoSacubitril/Valsartan56$74,347
JardianceEmpagliflozin45$61,955
TrulicityDulaglutide29$39,410
XareltoRivaroxaban17$21,403
Metoprolol Succinate155$3,714
Ezetimibe119$3,663
Eplerenone12$1,784
Isosorbide Dinitrate17$1,592
Irbesartan55$1,242
Rosuvastatin Calcium83$1,134
Spironolactone121$1,049
Atorvastatin Calcium114$1,006
Nifedipine ErNifedipine23$968

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$102,08489 claims
AstraZenecaFarxiga$7,015$86,01777 claims
Boehringer IngelheimJardiance$16$61,95545 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Delray Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →